Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy

PURPOSE: Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody–drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidkar, Anil P., Wang, Sinan, Bobba, Kondapa Naidu, Chan, Emily, Bidlingmaier, Scott, Egusa, Emily A., Peter, Robin, Ali, Umama, Meher, Niranjan, Wadhwa, Anju, Dhrona, Suchi, Dasari, Chandrashekhar, Beckford-Vera, Denis, Su, Yang, Tang, Ryan, Zhang, Li, He, Jiang, Wilson, David M., Aggarwal, Rahul, VanBrocklin, Henry F., Seo, Youngho, Chou, Jonathan, Liu, Bin, Flavell, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183825/
https://www.ncbi.nlm.nih.gov/pubmed/36917693
http://dx.doi.org/10.1158/1078-0432.CCR-22-3291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183825/
https://www.ncbi.nlm.nih.gov/pubmed/36917693
http://dx.doi.org/10.1158/1078-0432.CCR-22-3291

Ejemplares similares